(Linagliptin + metformin) SR is under clinical development by Dong Wha Pharma and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Linagliptin + metformin) SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Linagliptin + metformin) SR overview
DW-6013 is under development for the treatment of type 2 diabetes (T2D). The drug candidate is a fixed dose combination of linagliptin and metformin formulated in a sustained release form. The drug candidate is administered by oral route as a tablet. Linagliptin acts by targeting dipeptidyl peptidase 4. Metformin acts by targeting adenosine monophosphate activated protein kinase (AMPK).
Dong Wha Pharma overview
Dong Wha Pharma (Dongwha Pharm) is a pharmaceutical company that offers generic products. The company offers ethical drugs, over-the-counter products, quasi drugs, health foods and medical devices. Its products comprise clzapine tablets, valaboom, aripico tablets, intrinsic bubble cleanser, shampoos, tonic, danke cream and lotion. Dongwha Pharm provides muscle relaxants, antibiotics, dermatologicals, vitamins, anti-smoking agents, hepatic protectors, moega3 capsules, nutrients, tonics, cold remedies, mouth and teeth products and others. The company offers and drugs for alimentary system, cardiovascular and metabolic system, respiratory system, nervous system and urinary system. It operates in Incheon, Uiwang-si, Wonju-si, Dong-gu, Cheongju-si, and others. Dongwha Pharm is headquartered in Seoul, South Korea.
For a complete picture of (Linagliptin + metformin) SR’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
